Hodgkin's Disease
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you your search results in order of date.
1453 records returned
Aspirin kills 400% more people than H1N1 swine flu
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(NaturalNews) The CDC now reports that nearly 4,000 Americans have been killed by H1N1 swine flu. This number is supposed to sound big and scary, motivating millions of people to go out and pay good money to be injected with untested, unproven H1N1 vaccines. But let's put the number in perspective: Did you know that more than four times as many people are killed each year by common NSAID painkillers like aspirin?The July 1998 issue of The American Journal of Medicine explains it as follows:"Conservative calculations estimate that approximately 107,000 patients are hospitalized annually for nonsteroidal anti-inflammatory dr...
Source: NaturalNews.com - November 20, 2009 Category: Consumer Health Advice Source Type: news
Roles of Radiation Dose and Chemotherapy in the Etiology of Stomach Cancer as a Second MalignancyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Purpose: To evaluate the roles of radiation dose, chemotherapy, and other factors in the etiology of stomach cancer in long-term survivors of testicular cancer or Hodgkin lymphoma.Methods and Materials: We conducted a cohort study in 5,142 survivors of testicular cancer or Hodgkin lymphoma treated in the Netherlands between 1965 and 1995. In a nested case–control study, detailed information on treatment, smoking, gastrointestinal diseases, and family history was collected for 42 patients with stomach cancer and 126 matched controls. For each subject, the mean radiation dose to the stomach was estimated. Relative risks (R...
Source: International Journal of Radiation Oncology * Biology * Physics - November 19, 2009 Category: Radiology Authors: Alexandra W. van den Belt-Dusebout, Berthe M.P. Aleman, Gijs Besseling, Marie L. de Bruin, Michael Hauptmann, Mars B. van 't Veer, Ronald de Wit, Jacques G. Ribot, Evert M. Noordijk, J. Martijn Kerst, Jourik A. Gietema, Flora E. van Leeuwen Tags: Stomach Source Type: journals
[Prognostic value of FDG-PET in Hodgkin lymphoma for posttreatment evaluation. Long-term follow-up results.]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion: Our results, in accordance with literature, clearly indicate that patients with negative FDG-PET results are unlikely to progress or relapse during a long follow-up. However, false positive uptake is a problem. We have investigated the effect of age, histological subtype, clinical stage and the type of treatment on the accuracy, but on the basis of these facts we could not find any significant difference. However, the date of the investigation influenced the results: before 2000 the number of false results was significantly higher than after that time, which shows the importance of investigators' experience.
...
Source: Orvosi Hetilap - November 19, 2009 Category: Journals (General) Authors: Molnár Z, Simon Z, Borbényi Z, Deák B, Galuska L, Keresztes K, Miltényi Z, Marton I, Rosta A, Schneider T, Trón L, Várady E, Illés A Tags: Orv Hetil Source Type: journals
Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoidesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions Our results confirm that phototherapy is a safe, effective and well-tolerated, first-line therapy in patients with early-stage cutaneous T-cell lymphoma, with prolonged disease-free remissions being achieved. It suggests that narrowband UVB is at least as effective as PUVA for treatment of early-stage MF. (Source: Journal of the European Academy of Dermatology and Venereology)
Source: Journal of the European Academy of Dermatology and Venereology - November 19, 2009 Category: Dermatology Authors: P Ponte, V Serrão, M Apetato Source Type: journals
Diagnosis of childhood cancer.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Childhood cancer is uncommon but remains the leading cause of disease-related death in children. Symptoms are often vague or insidious; they may suggest a more common alternative diagnosis, and they are quite different from those associated with adult malignancy. The skilled office practitioner must consider cancer as a diagnosis when symptoms/signs persist or when multiple symptoms point toward a possible diagnosis of malignancy. Early diagnosis is critical, as survival rates have increased dramatically over the past decades. Prolonged delay in diagnosis is common, especially for brain tumors and certain lymphomas (Ho...
Source: Primary Care - November 17, 2009 Category: Primary Care Authors: Raab CP, Gartner JC Tags: Prim Care Source Type: journals
Survivorship: adult cancer survivors.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
During the next decade, a rapid increase in the number of new cancer diagnoses in the population as well as a growing number of cancer survivors can be expected. Cancer is anticipated to exceed cardiovascular disease as the primary cause of mortality in the United States population. Despite efforts in tobacco control, the aging of the population and obesity epidemic will contribute toward the increasing incidence of cancer. Although oncology specialists will continue to play a critical role in the diagnosis and initial treatment of patients with cancer, primary care providers will need to play an expanding role in the ...
Source: Primary Care - November 17, 2009 Category: Primary Care Authors: Ganz PA Tags: Prim Care Source Type: journals
Microsoft co-founder Allen diagnosed with cancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Microsoft co-founder Paul Allen has been diagnosed with non-Hodgkin's lymphoma, more than 25 years after he was treated for Hodgkin's disease, a spokesman at his company Vulcan Inc. told CNN on Monday. (Source: CNN.com - Health)
Source: CNN.com - Health - November 17, 2009 Category: Consumer Health News Source Type: news
Primary Nasopharyngeal non-Hodgkin lymphomas: a retrospective review of 26 Moroccan patients.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion:
From our study, we conclude that histological characteristics, principle of treatment and outcome of primary NNHL patients are particular and more studies have to be directed . (Source: BMC Ear, Nose and Throat Disorders)
Source: BMC Ear, Nose and Throat Disorders - November 17, 2009 Category: ENT & OMF Authors: Wafa AllamNabil IsmailiSanaa ElmajjaouiBel ElgueddariMohamed IsmailiHassan Errihani Source Type: journals
Video: 'Survivor' Winner's Cancer BattleEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
"Survivor" winner Ethan Zohn is documenting his battle with Hodgkins Disease in the hopes of educating others. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 13, 2009 Category: Consumer Health News Source Type: news
Mistletoe therapy as a therapeutic option in a child with lymphomatoid papulosis/CD 30-positive cutaneous lymphoproliferative papulosisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In conclusion we present a patient with a rare skin disease (LP) with lymph node involvement who is successful treated with mistletoe as a new promising therapeutic option for patients with lymphomatoid papulosis. Further studies should be initiated. (Source: European Journal of Integrative Medicine)
Source: European Journal of Integrative Medicine - November 13, 2009 Category: Complementary Medicine Authors: G. Kameda, K. Michael, A. Längler Source Type: journals
Hypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions:
The canine DLC1 is constructed highly similarly to the human gene, which has been shown to be an important tumor suppressor in many forms of cancer. As in human NHL, the promoter CpG island of DLC1 in canine NHL samples is abnormally hypermethylated, relative to normal lymphoid tissue. This study confirms that hypermethylation occurs in canine cancers, further supporting the use of companion dogs as comparative models of disease for evaluation of carcinogenesis, biomarker diagnosis, and therapy. (Source: BMC Genetics - Latest articles)
Source: BMC Genetics - Latest articles - November 13, 2009 Category: Genetics & Stem Cells Authors: Jeffrey BryanMohamed JabbesLinda BerentGerald ArthurKristen TaylorKerry RissettoCarolyn HenryFarah RahmatpanahWendi RankinJose VillamilMichael LewisCharles Caldwell Source Type: journals
Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CONCLUSIONS: Asymptomatic patients without morphological residues and an early stage of disease do not need a routine FDG-PET/CT for follow-up. Asymptomatic patients with morphological residues should receive routine follow-up FDG-PET/CT for the first 24 months. Only patients with advanced initial stage do need a routine follow-up FDG-PET/CT beyond 24 months.
PMID: 19914963 [PubMed - as supplied by publisher] (Source: Ann Oncol)
Source: Ann Oncol - November 13, 2009 Category: Cancer & Oncology Authors: Petrausch U, Samaras P, Veit-Haibach P, Tschopp A, Soyka JD, Knuth A, Hany TF, Mischo A, Renner C, Schaefer NG Tags: Ann Oncol Source Type: journals
Allogeneic transplantation for children and adolescents with Hodgkin lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
(Source: Blood)
Source: Blood - November 12, 2009 Category: Hematology Authors: Schmitz, N., Sureda, A., Dini, G., Claviez, A., on behalf of the Lymphoma and Pediatric diseases Working Parties Tags: CORRESPONDENCE Source Type: journals
FDA approves romidepsin (Istodax®) for treatment of cutaneous T-cell lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: BioSpace
Area: News
The FDA has approved romidepsin (Istodax®), a histone deacetylase (HDAC) inhibitor, for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. CTCL is a type of non-Hodgkin's lymphoma, but caused by a mutation of T cells, unlike most non-Hodgkin's lymphomas which are generally of B-cell origin. Approval was based upon two prospective multicentre, single-arm clinical studies in 167 patients, which reported overall objective disease response rates (primary efficacy endpoint) of 34% and 35%. The most common adverse reactions reported i...
Source: NeLM - Oncology - November 9, 2009 Category: Cancer & Oncology Source Type: organizations
[Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin s lymphoma.]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
This guideline is a prerequisite for the quality management in the treatment of non-Hodgkon- lymphomas in patients with relapsed or refractory follicular lymphoma after rituximab therapy and as consolidation therapy after first remission following CHOP like treatment using radioimmunotherapy. It is based on an interdisciplinary consensus and contains background information and definitions as well as specified indications and detailed contraindications of treatment. Essential topics are the requirements for institutions performing the therapy. For instance, presence of an expert for medical physics, intense cooperation ...
Source: Nuklearmedizin - November 9, 2009 Category: Radiology Authors: Fischer M, Grünwald F, Knapp WH, Trümper L, von Schilling C, Dreyling M Tags: Nuklearmedizin Source Type: journals
Cost Effectiveness and Screening Interval of Lipid Screening in Hodgkin's Lymphoma Survivors [Hematologic Malignancies]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion
Lipid screening in survivors of HL, with statin therapy for screen-positive patients, improves survival and is cost effective. A screening interval of 3 years seems reasonable in the long-term follow-up of survivors of HL. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Chen, Punglia, Kuntz, Mauch, Ng Tags: Radiation, Cost Effectiveness, Outcomes Research Hematologic Malignancies Source Type: journals
Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 [Hematologic Malignancies]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion
In a large, randomized trial, the efficacies of Stanford V and ABVD were comparable when given in combination with appropriate radiotherapy. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Hoskin, Lowry, Horwich, Jack, Mead, Hancock, Smith, Qian, Patrick, Popova, Pettitt, Cunningham, Pettengell, Sweetenham, Linch, Johnson Tags: Chemotherapy, Combined Modality Hematologic Malignancies Source Type: journals
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [Hematologic Malignancies]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion
Oral lenalidomide monotherapy produces durable responses with manageable adverse events in patients with relapsed/refractory indolent NHL, warranting further investigation of treatment for indolent NHL. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Witzig, Wiernik, Moore, Reeder, Cole, Justice, Kaplan, Voralia, Pietronigro, Takeshita, Ervin-Haynes, Zeldis, Vose Tags: Clinical Trials, Chemotherapy Hematologic Malignancies Source Type: journals
Pivotal Data Published In The Journal Cancer Demonstrate That TREANDA Induced Durable Responses In Relapsed Indolent Non-Hodgkin's LymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Cephalon, Inc. (Nasdaq: CEPH) announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 6, 2009 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Pivotal Data Published In The Journal Cancer Demonstrate That TREANDA Induced Durable Responses In Relapsed Indolent Non-Hodgkin's LymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Cephalon, Inc. (Nasdaq: CEPH) announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab. (Source: Lymphoma / Leukemia News From Medical News Today)
Source: Lymphoma / Leukemia News From Medical News Today - November 6, 2009 Category: Hematology Tags: Lymphoma / Leukemia / Myeloma Source Type: news
New Data On Bendamustine Offers Hope To Non-Hodgkin's Lymphoma Patients Resistant To Standard TherapyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
New data published today in the journal, Cancer, reveals that three quarters (75%) of patients with indolent B-cell non-Hodgkin's lymphoma (iNHL), responded to treatment with Bendamustine following a single-arm, multicentre study. Significantly, all patients participating in the study had become resistant or were unresponsive to rituximab (the standard treatment for the disease) when used either as a single agent or in combination with other therapies. Professor Brad S. (Source: Lymphoma / Leukemia News From Medical News Today)
Source: Lymphoma / Leukemia News From Medical News Today - November 6, 2009 Category: Hematology Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Case Report: First Reported Case of Disease: Peliosis Hepatis as Cardinal Symptom of Hodgkin's Lymphoma.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
We present the case of a 25-year-old woman with a history of weakness, weight loss, anemia, and elevated liver enzymes. Outpatient diagnostic evaluation, including abdominal ultrasound and endoscopies, revealed no conclusive explanation for the clinical picture and the patient was admitted to our clinic. Because of the hepatosplenomegaly together with the elevated liver enzymes, one of our differential diagnoses was that of liver disease. To clarify this, we performed a minilaparoscopy, which showed multiple diffuse distributed spots of livid color without clear margins distributed all over both liver lobes. A biopsy taken...
Source: The Oncologist - November 4, 2009 Category: Cancer & Oncology Authors: Kleger A, Bommer M, Kunze M, Klaus J, Leithaeuser F, Wegener M, Adler G, Dikopoulos N Tags: Oncologist Source Type: journals
[Long-term efficacy of autologous stem cell transplantation for stage IV mycosis fungoides.]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
We report the case of a young man still in complete remission for transformed mycosis fungoides 14 years after autologous stem cell transplantation. CASE REPORT: A 25-year-old man presenting eczema-like patches since childhood was treated by chemotherapy for multiple lymphadenopathies considered as Hodgkin's lymphoma. He was referred with diffuse skin tumours and infiltrated patches. Histology of tumour samples revealed atypical T-cell infiltrate with epidermotropism and presence of more than 25% of large CD30-positive cells. Non-infiltrated patches showed small T-cell lymphoma with epidermotropism. Histological verificati...
Source: Annales de Dermatologie et de Cenereologie - November 1, 2009 Category: Dermatology Authors: Di Lucca-Chrisment J, Maubec E, Grossin M, Marinho E, Varet B, Maillard H, Crickx B Tags: Ann Dermatol Venereol Source Type: journals
Age-related EBV-associated B-cell lymphoproliferative disorders: Diagnostic approach to a newly recognized clinicopathological entityEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
EBV is prevalent among healthy individuals, and is implicated in numerous reactive and neoplastic processes in the immune system. The authors originally identified a series of senile or age-related EBV-associated B-cell lymphoproliferative disorders (LPD) bearing a resemblance to immunodeficiency-associated ones, which may be associated with immune senescence in the elderly and which are now incorporated into the 2008 World Health Organization lymphoma classification as EBV-positive diffuse large B-cell lymphoma (DLBCL) of the elderly. This newly described disease is pathologically characterized by a proliferation of atypi...
Source: Pathology International - October 30, 2009 Category: Pathology Authors: Yoshie Shimoyama, Naoko Asano, Masaru Kojima, Satoko Morishima, Kazuhito Yamamoto, Takashi Oyama, Tomohiro Kinoshita, Shigeo Nakamura Source Type: journals
Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donorsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In conclusion, 7.5 µg/kg per day lenograstim proved to be safe and effective for mobilizing hematopoietic stem cells for allogeneic transplantation. Long-term monitoring of healthy PBSC donors remains important to guarantee the safety standards of PBSC mobilization and collection. (Source: Blood)
Source: Blood - October 29, 2009 Category: Hematology Authors: Holig, K., Kramer, M., Kroschinsky, F., Bornhauser, M., Mengling, T., Schmidt, A. H., Rutt, C., Ehninger, G. Tags: Hematopoiesis and Stem Cells, Transfusion Medicine, Transplantation, Free Research Articles, Clinical Trials and Observations Source Type: journals
Plasmacytoid Dendritic Cells: Physiologic Roles and Pathologic StatesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Plasmacytoid dendritic cells (PDCs) have perplexed pathologists for decades, undergoing multiple adjustments in nomenclature as their lineage and functions have been characterized. Although PDCs account for less than 0.1% of peripheral blood mononuclear cells, they serve as a principal source of interferon-[alpha] and are also known as interferon-I producing cells (IPCs). Upon activation in vitro, they can differentiate into dendritic cells, and recent studies have substantiated a potential role in antigen presentation. Thus, PDCs may act as a link between innate and adaptive immunity. Normally found in small quantities in...
Source: Advances in Anatomic Pathology - October 29, 2009 Category: Pathology Tags: Review Articles Source Type: journals
Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion: Sixty-nine per cent of patients with residual FDG avidity after ABVD were free of disease after consolidative RT, indicating a majority of patients with persistent lymphoma can be cured by sterilizing this PET-positive disease. (Source: Annals of Oncology)
Source: Annals of Oncology - October 27, 2009 Category: Cancer & Oncology Authors: Sher, D. J., Mauch, P. M., Van Den Abbeele, A., LaCasce, A. S., Czerminski, J., Ng, A. K. Tags: hematologic malignacies Source Type: journals
One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abstract The aim of the study was to assess the long-term efficacy and safety of Infliximab therapy in the treatment of patients with
Behçet’s disease refractory to standard immunosuppressive agents. Twenty-one patients that did not respond to corticosteroids
and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular
and/or CNS involvement were enrolled. Eighteen patients completed the study up to 54 weeks. Stable doses of prednisone (<10 mg/day)
were permitted, immunosuppressants were discontinued at least 4 weeks prior b...
Source: Rheumatology International - October 26, 2009 Category: Rheumatology Tags: Rheumatology International Source Type: journals
Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Presence of normal plasma cells (PCs), hemodilution of bone marrow aspirate, and changes in the immunophenotype are important considerations in minimal residual disease (MRD) assessment in multiple myeloma (MM). We evaluated 124 subjects-107 with MM, 11 with Hodgkin lymphoma, and 6 allogeneic stem cell transplantation donors-for the immunophenotype of neoplastic, reactive, and normal PCs respectively. Of the patients with MM, 36 were evaluated for MRD and 23 for a change in immunophenotype after chemotherapy. The immunophenotype of normal and reactive PCs was similar and differed from that of neoplastic PCs with respec...
Source: American Journal of Clinical Pathology - October 24, 2009 Category: Pathology Authors: Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P Tags: Am J Clin Pathol Source Type: journals
Significant CD5 expression on normal stage 3 hematogones and mature B Lymphocytes in bone marrow.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
B-cell maturation from hematogones to mature B cells in bone marrow exhibits a consistent, complex spectrum of sequential antigen expression. CD5 expression, however, has not been characterized. We studied the dynamics of CD5 expression on developing B cells by 4-color flow cytometry in 32 patients, aged 9 months to 63 years, with hematogone hyperplasia (>3.5% of total events). The mean percentage of hematogones was 8.1%. We demonstrate consistent CD5 expression on normal, polytypic B cells in a continuum, predominantly at later stages of maturation, specifically on stage 3 hematogones and mature B cells. Awareness ...
Source: American Journal of Clinical Pathology - October 24, 2009 Category: Pathology Authors: Fuda FS, Karandikar NJ, Chen W Tags: Am J Clin Pathol Source Type: journals
Malignant lymphoproliferative disorders extending into the orbit from the paranasal sinuses.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CONCLUSION: Presenting symptoms of malignant orbital lymphoproliferative disorders extending from the paranasal sinuses include mass effect occasionally with infiltrative and inflammatory characteristics accompanied by symptoms of sinus disease. On imaging, a soft tissue mass in the sinuses and orbit with bone destruction is commonly seen. Biopsy is essential for conclusive diagnosis. Treatment should be initiated promptly as local symptoms are frequently relieved and survival is possible, especially in cases of NHL.
PMID: 19839889 [PubMed - in process] (Source: Orbit)
Source: Orbit - October 22, 2009 Category: Opthalmology Authors: Peleg A, Heran MK, White VA, Chang WY, Rootman J Tags: Orbit Source Type: journals
Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
High-dose chemotherapy (HDC) conditioning given in association with autologous stem cell transplantation (ASCT) or reduced-intensity conditioning (RIC) with allogeneic stem cell transplantation (alloSCT) are established treatment approaches for patients with chemotherapy-sensitive, relapsed, aggressive, or low-grade non-Hodgkin's lymphoma (NHL). These approaches have been shown to be the only curative option for patients with relapsed NHL. Despite data suggesting that prolonged event-free survival can be achieved with SCT combined with HDC, there are problems that may limit the utility of this approach for a broad pati...
Source: The Oncologist - October 22, 2009 Category: Cancer & Oncology Authors: Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A Tags: Oncologist Source Type: journals
Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin's lymphoma.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Radioimmunotherapy (RIT) combines the use of targeted monoclonal antibodies with radionuclides for the treatment of non-Hodgkin's lymphoma (NHL), taking advantage of its inherent radiosensitivity. A number of trials have shown significantly higher response rates and longer progression-free survival times in patients treated with the CD20-targeted radioimmunoconjugate yttrium-90-ibritumomab tiuxetan compared with the standard of care. Furthermore, these benefits have also been shown in heavily pretreated patients who relapsed or were resistant to rituximab. Currently, a number of different treatment regimens and strateg...
Source: The Oncologist - October 22, 2009 Category: Cancer & Oncology Authors: Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M Tags: Oncologist Source Type: journals
Sperm quality before treatment in patients with early stage Hodgkin lymphoma enrolled in EORTC-GELA Lymphoma Group trials.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusions Ninety percent of males with Hodgkin lymphoma have good or intermediate sperm quality. Three percent are azoospermic. There is an association between sperm quality and the presence or absence of B-symptoms, in particular fever and night sweats. With modern fertilization techniques, sperm quality before treatment is good enough for future fatherhood in most early-stage Hodgkin lymphoma patients.
PMID: 19850901 [PubMed - as supplied by publisher] (Source: Haematologica)
Source: Haematologica - October 22, 2009 Category: Hematology Authors: van der Kaaij MA, Heutte N, van Echten-Arends J, Raemaekers JM, Carde P, Noordijk EM, Fermé C, Thomas J, Eghbali H, Brice P, Bonmati C, Henry-Amar M, Kluin-Nelemans HC Tags: Haematologica Source Type: journals
Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approachEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Burkitt Lymphoma (BL) is listed in the World Health Organization (WHO) classification of lymphoid tumours as an 'aggressive B-cell non-Hodgkin's lymphoma', characterized by a high degree of proliferation of the malignant cells and deregulation of the c-MYC gene. The main diagnostic challenge in BL is to distinguish it from diffuse large B-cell lymphoma (DLBCL). While in children BL and DLBCL types probably do not differ clinically, and the differential diagnosis between BL and DLBCL may theoretically appear clear-cut, in adults daily practice shows the existence of cases that have morphological features, immunophenotypic a...
Source: Hematological Oncology - October 20, 2009 Category: Hematology Authors: Cristiana Bellan, Lazzi Stefano, De Falco Giulia, Emily A Rogena, Leoncini Lorenzo Source Type: journals
Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology [Pediatric Oncology]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion
Vinblastine is highly efficient in relapsed ALCL and may produce durable remissions. The optimal treatment duration still has to be assessed. These results should be borne in mind when designing future phase II studies with the targeted therapies directed against anaplastic lymphoma kinase. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2009 Category: Cancer & Oncology Authors: Brugieres, Pacquement, Le Deley, Leverger, Lutz, Paillard, Baruchel, Frappaz, Nelken, Lamant, Patte Tags: Chemotherapy, Non-hodgkin's Lymphoma Pediatric Oncology Source Type: journals
Clinicopathological correlates of pediatric head and neck cancerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion</b> : The most common manifestation of the malignant lesions in the pediatric age group was with a history of an enlarging, painless neck swelling. Still, an insignificant lump in the neck or recurrent bleeding from nose may be the manifestation of an underlying cancer. (Source: Journal of Cancer Research and Therapeutics)
Source: Journal of Cancer Research and Therapeutics - October 16, 2009 Category: Cancer & Oncology Authors: Sengupta Subhabrata, Pal Ranabir Source Type: journals
Primary effusion lymphoma involving three body cavitiesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
We describe herein a case of PEL affecting three body cavity sites in an immunocompetent patient. A 69-year-old HIV-negative man presented with upper gastrointestinal bleeding and ascites. An examination of the fluid by cytology showed large atypical lymphocytes with abundant basophilic cytoplasm, either central or eccentric nuclei having irregular outlines, and multiple prominent nucleoli. The neoplastic cells showed positive staining for CD45, CD3, HHV8 latent nuclear antigen (LNA), and Epstein-Barr virus-encoded RNA. A diagnosis of PEL was rendered. Despite chemotherapy and valganciclovir, the disease progressed to invo...
Source: CytoJournal - October 10, 2009 Category: Pathology Authors: Brimo Fadi, Popradi Gizelle, Michel Rene P, Auger Manon Source Type: journals
Primary cutaneous Hodgkin's lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
We report a case of a man treated with combination systemic chemotherapy for PCHD, and review the available literature. (Source: Clinical And Experimental Dermatology)
Source: Clinical And Experimental Dermatology - October 9, 2009 Category: Dermatology Authors: M. Mukesh, D. Shuttleworth, P. Murray Source Type: journals
[Therapeutic management of central nervous system lymphomas in a single hematological institute.]Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Conclusion: In primary central nervous system lymphoma, basic treatment HD methotrexate together with intrathecal combination of methotrexate + cytosin-arabinosid + dexamethasone followed by whole-brain irradiation of at least 30 Gy could produce a medium response rate in our study. In case of relapse or progression, other salvage regimens containing HD Ara-C alternating with HD MTX could reduce the treatment failure, as well. After therapy PET/CT was negative in five patients with prolonged disease-free survival.
PMID: 19812012 [PubMed - in process] (Source: Orvosi Hetilap)
Source: Orvosi Hetilap - October 9, 2009 Category: Journals (General) Authors: Iványi JL, Marton E, Plander M, Gyánó G, Czumbil L, Tóth C Tags: Orv Hetil Source Type: journals
Hodgkin lymphoma: current issuesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
A par dos extraordinários avanços obtidos no tratamento do linfoma de Hodgkin, diversos desafios persistem na compreensão da biologia da doença, e na determinação de alternativas que maximizem a eficácia terapêutica e minimizem as toxicidades imediatas e tardias. O objetivo deste artigo é apresentar informações recentes que têm relevância imediata para aqueles que cuidam de pacientes com linfoma de Hodgkin (LH).Knowing the extraordinary advances obtained in the treatment of Hodgkin's lymphoma, several challenges persist related to the biology of the disease and to the determination of alternatives that maximiz...
Source: Revista Brasileira de Hematologia e Hemoterapia - October 2, 2009 Category: Hematology Source Type: journals
Is there a role for allogeneic haemopoietic stem cell transplants (HSCT) in patients with Hodgkin's disease?Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Allogeneic HSCT was first investigated in selected patients with advanced HD and proved that long-term survival improved for some patients who failed many other lines of therapy. There are 4 studies reporting myeloablative conditioning in preparation for allogeneic HSCT. Although overall survival was above 44%, the high transplant-related mortality convinced most hematologists that allogeneic HSCT was not a real option for patients with HD. The development of reduced intensity conditioning regimens (RIC) in the late nineties, appeared as an opportunity to again test allogeneic HSCT in HD. RIC transplants are associated wit...
Source: Revista Brasileira de Hematologia e Hemoterapia - October 2, 2009 Category: Hematology Source Type: journals
Brazilian experience using high-dose sequential therapy (HDS) followed by autologous hematopoietic stem cell transplantation (ASCT) for malignant lymphomasEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Using the overall survival (OS), disease free survival (DFS) and progression free survival (PFS), as well as associated toxicity, the purpose of this work was to evaluate the effectiveness of HDS followed by ASCT as salvage therapy. A retrospective analysis was performed of 106 patients with high grade non-Hodgkin lymphoma receiving HDS followed by ASCT, between 1998 and 2006. Median age was 45 years (Range: 8-65), with 66 (62%) men. Histopathological classification was: 78% DLBCL patients, 12% T and anaplastic and 9% Mantle cell lymphomas; 87% had B cell and 12% T cell lymphomas; 83% were stage III-IV (Ann Arbor Staging),...
Source: Revista Brasileira de Hematologia e Hemoterapia - October 2, 2009 Category: Hematology Source Type: journals
Bleomycin induced urethral stricture in Hodgkin's diseaseEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Tapkire Ritesh, Kathiresan N, Satheesan BIndian Journal of Urology 2009 25(3):398-400Bleomycin is a glycoprotein that is extensively used in combination with other anti-cancer agents because of its relative lack of hematological and gastrointestinal toxicity. However, pulmonary toxicity is common with bleomycin and limits its therapeutic utility. Urethral stricture as a result of bleomycin toxicity has not been reported in literature. In this case report, a young male patient who developed urethral stricture after bleomycin-based chemotherapy is described and the possible effects of bleomycin on the urethra are discussed. ...
Source: Indian Journal of Urology - October 1, 2009 Category: Urology & Nephrology Authors: Tapkire Ritesh, Kathiresan N, Satheesan B Source Type: journals
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphomaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
We examined the influence of our previously reported 25-microRNA signature for cHL on clinical outcome in 89 homogeneously treated cHL patients with a median follow-up of 80 months. Patients with low miR-135a expression had a higher probability of relapse (P = .04) and a shorter disease-free survival (P = .02). Functional analysis of cHL cell lines showed that mature miR-135a levels increased after pre–miR-135a transfection, causing apoptosis and decreased cell growth. Target analysis showed a direct regulation by miR-135a of JAK2, a cytoplasmic tyrosine kinase involved in a specific subset of cytokine receptor signa...
Source: Blood - October 1, 2009 Category: Hematology Authors: Navarro, A., Diaz, T., Martinez, A., Gaya, A., Pons, A., Gel, B., Codony, C., Ferrer, G., Martinez, C., Montserrat, E., Monzo, M. Tags: Lymphoid Neoplasia Source Type: journals
Impact of Genotype Misclassification on Genetic Association Estimates and the Bayesian AdjustmentEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Genotypes of single nucleotide polymorphisms are subject to misclassification. If ignored, such misclassification can seriously distort the estimated genotype effects on the disease or outcome of interest. Validation data (gold standard or replicated surrogates) are required to assess the degree of misclassification and make adjustments. In practice, gold standard measurements may be unavailable or impractical. Collecting replicated surrogates is a reasonable option for validation data. In most practical applications, collecting replicated surrogates on all study subjects is not feasible; however, obtaining replicated surr...
Source: American Journal of Epidemiology - October 1, 2009 Category: Epidemiology Authors: Hossain, S., Le, N. D., Brooks-Wilson, A. R., Spinelli, J. J. Tags: RESEARCH-ARTICLE Source Type: journals
Management of immunocompetent patients with primary central nervous system lymphoma.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Primary central nervous system (CNS) lymphoma (PCNSL) is a non-Hodgkin lymphoma that arises within and is confined to the CNS. Recent data have suggested an increasing incidence in immunocompetent individuals, with a peak of incidence between 60 and 70 years of age. Patients with PCNSL present mostly with symptoms of increased intracranial pressure. The clinical management of these patients remains controversial, and the optimal treatment for patients with PCNSL has not yet been defined. Surgery, even if macroscopically radical, does not improve survival because of the multifocal and infiltrative nature of PCNSL; furth...
Source: Clinical Lymphoma and Myeloma - October 1, 2009 Category: Cancer & Oncology Authors: Chimienti E, Spina M, Vaccher E, Tirelli U Tags: Clin Lymphoma Myeloma Source Type: journals
Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Examination of the clinical utility of SN38 (10-hydroxy-7-ethyl-camptothecin), the active metabolite of CPT-11, has not been possible to date due to poor solubility of SN38. Here we evaluated the activity of EZN-2208, a water-soluble polyethyleneglycol-SN38 conjugate, in pre-clinical models of Burkitt's non-Hodgkin's lymphoma (NHL) (Raji and Daudi), and follicular NHL (DoHH2). In vitro, the IC50 of EZN-2208 ranged from 3-24 nM, which was 30- to 45-fold lower than CPT-11 or 2.5- to 3.5-fold higher than SN38. In both an early-disease Raji model and an advanced-disease Daudi model, treatment with multiple doses of EZN-220...
Source: Haematologica - September 30, 2009 Category: Hematology Authors: Sapra P, Kraft P, Mehlig M, Malaby J, Zhao H, Greenberger LM, Horak ID Tags: Haematologica Source Type: journals
Lymphoma in Adolescents and Young AdultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Non-Hodgkin (NHL) and Hodgkin (HL) lymphomas are represented prominently in the adolescent and young adult (AYA) population. These diseases represent 11% of total cancer diagnoses in children, 4% in those 40 years of age and older, and 13% in AYA (aged 15–39 years). Although age-adjusted incidence rates of NHL increase with age, the more aggressive lymphomas are seen more commonly in the younger population with a transition to low-grade, indolent subtypes as the population ages. Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma make up the most common subtypes in ...
Source: Seminars in Oncology - September 30, 2009 Category: Cancer & Oncology Authors: Samantha M. Jaglowski, Erica Linden, Amanda M. Termuhlen, Joseph M. Flynn Tags: Impact of Malignant disease on Young Adults II Source Type: journals
Malignant lymphoma of the testis: a study of 12 cases.Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CONCLUSION: Testicular lymphoma is a rare and deadly form of extra-nodal lymphoma. Survival was significantly different in early stage I/II and IPI low-risk versus advanced stage IV and IPI high-risk disease. Randomized, prospective treatment trials may help to establish better treatment strategies.
PMID: 19829735 [PubMed - as supplied by publisher] (Source: Canadian Urological Association Journal)
Source: Canadian Urological Association Journal - September 30, 2009 Category: Urology & Nephrology Authors: Lantz AG, Power N, Hutton B, Gupta R Tags: Can Urol Assoc J Source Type: journals
